exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274471 RNA Name: hsa-miR-1286 RNA Type: miRNA Chromosome: chr22 Starnd: - Coordinate: Start Site(bp): 20249145 End Site(bp): 20249165 External Links: hsa-miR-1286

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand TRIO chr5 14143342 14532128 + TXLNA chr1 32179675 32198285 + CSNK1E chr22 38290691 38318084 - NT5DC2 chr3 52524385 52535054 - ERLIN1 chr10 100150094 100186033 - BTG2 chr1 203305491 203309602 + GOLGA3 chr12 132768914 132829078 - ABCA2 chr9 137007234 137028922 - SSR2 chr1 156009048 156020951 - LUZP1 chr1 23084023 23177808 - RUBCN chr3 197668867 197749727 - CBX6 chr22 38861422 38872249 - KMT2A chr11 118436490 118526832 + LAMTOR1 chr11 72085895 72103297 - PHF12 chr17 28905250 28951771 - NPTX1 chr17 80466834 80477843 - ZXDB chrX 57591652 57597545 + PHLDA3 chr1 201464278 201469237 - NIPSNAP1 chr22 29554808 29581327 - IGDCC3 chr15 65327127 65378002 - TNRC6B chr22 40044817 40335808 + DNAJC30 chr7 73680918 73683453 - ALG10B chr12 38316762 38329721 + RBM4 chr11 66638617 66668374 + ABHD14B chr3 51968510 51983409 - ATXN2L chr16 28823035 28837237 + CPA4 chr7 130293134 130324180 + FGFR1 chr8 38400215 38468834 - HDGF chr1 156742109 156766925 - ATP8B2 chr1 154325553 154351304 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001588 chr6 26204839 26205043 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC010327.5 chr19 55216660 55221616 + AC016876.2 chr17 7581964 7584086 - AC124068.2 chr15 89335053 89336161 + DNAAF4-CCPG1 chr15 55355248 55498360 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.